淋巴结检出数与新辅助治疗后淋巴结阴性胰腺导管腺癌总生存及复发时间的关联
该研究基于麻省总医院胰腺切除数据库和国家癌症数据库(NCDB),探讨淋巴结检出数(LNY)与新辅助治疗(NAT)后淋巴结阴性(N0)胰腺导管腺癌(PDAC)患者总生存(OS)和复发时间(TTR)的关系。两个独立队列均显示LNY≥22与更长的中位OS相关,多因素分析提示每检出1枚淋巴结LNY是生存的独立预测因子。
要点
- NAT后N0 PDAC患者中,LNY≥22与更长的中位OS和TTR相关。
- 每检出1枚淋巴结,LNY是多因素分析中的独立生存预测因子。
- 两个独立数据集验证了LNY与肿瘤学结局的关联。
核心结论
- 在NAT后行胰十二指肠切除术的N0 PDAC患者中,LNY与改善的肿瘤学结局相关,两个独立数据集结果一致。
研究设计与样本
- 回顾性队列研究,纳入麻省总医院胰腺切除数据库233例病理T分期I至III、淋巴结阴性且接受NAT后胰十二指肠切除术的PDAC患者。
- 利用NCDB识别2029例同类患者,以log-rank检验最优分割点确定LNY截断值为22枚淋巴结。
- 采用单因素和多因素分析评估OS和TTR。
主要发现
- 麻省总医院队列中,LNY≥22与更长的中位OS相关(59 vs 25个月,P<0.001),并与更长的TTR相关(32 vs 14个月,P=0.019)。
- 麻省总医院队列多因素分析中,每检出1枚淋巴结LNY是生存的独立预测因子(HR 0.97,95%CI 0.95-0.99,P=0.034)。
- NCDB队列中,LNY≥22与更长的中位OS相关(49 vs 33个月,P<0.001)。
- NCDB队列多因素分析中,每检出1枚淋巴结LNY是生存的独立预测因子(HR 0.99,95%CI 0.98-0.99,P<0.001)。
临床怎么用
- 对于NAT后行胰十二指肠切除术的N0 PDAC患者,应重视淋巴结检出数,LNY≥22与更优生存和复发结局相关。
局限性
- LNY影响NAT后N0患者结局的具体机制尚待进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether lymph node yield (LNY) is associated with improved overall survival (OS) and time to recurrence (TTR) in patients with node-negative pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant therapy (NAT). BACKGROUND: LNY has been associated with survival in solid gastrointestinal cancers, including PDAC. METHODS: Patients with pathologic T stage I to III, node-negative (N0), PDAC treated with NAT followed by pancreatoduodenectomy were identified in the Massachusetts General Hospital pancreatectomy database and the National Cancer Database (NCDB). A cutoff point of 22 nodes was identified in the NCDB using the point with the optimal (log-rank test) split. OS and TTR were evaluated using univariate and multivariable analyses. RESULTS: In the Massachusetts General Hospital cohort, 233 node-negative patients following NAT were included. A LNY ≥ 22 was associated with prolonged median OS (59 vs 25 mo, P <0.001) and prolonged TTR (32 vs 14 mo, P =0.019). On multivariable analysis, LNY was an independent predictor of survival (HR 0.97, 95% CI: 0.95-0.99, P =0.034) per sampled node. In the NCDB, 2029 node-negative patients following NAT were included. A LNY ≥ 22 was associated with prolonged median OS (49 vs 33 mo, P <0.001). On multivariable analysis, LNY was an independent predictor of survival (HR 0.99, 95% CI: 0.98-0.99, P <0.001) per sampled node. CONCLUSIONS: LNY was associated with improved oncologic outcomes in patients treated with NAT followed by pancreatoduodenectomy in two independent data sets. Responsible mechanisms by which LNY impacts the outcomes of node-negative patients following NAT warrant further exploration.
引用
- Servin-Rojas M, Fong ZV, Fernandez-Del Castillo C, et al. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Ann Surg. 2024. PMID: 38953216. doi:10.1097/SLA.0000000000006432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。